Roche Reports Positive Phase III Results for Multiple Sclerosis Treatment Fenebrutinib

Roche announced positive results from its Phase III FENhance 1 study, evaluating the investigational drug fenebrutinib for relapsing multiple sclerosis (RMS). The study demonstrated that fenebrutinib reduced the annualized relapse rate by 51% compared to teriflunomide, confirming its high clinical efficacy. These findings align with the FENhance 2 study, which showed a 59% reduction, effectively translating to approximately one relapse every 17 years. Additionally, the trial met its secondary endpoints, showing statistically significant reductions in brain lesions. As a potential first-in-class BTK inhibitor, fenebrutinib represents a significant advancement in treating both relapsing and primary progressive forms of the disease. Investors view these clinical successes as a strong fundamental driver for Roche's future market position and regulatory approval prospects.